Analyst Price Targets — ADAPY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2024 6:07 am | Arthur He | H.C. Wainwright | $4.00 | $1.37 | TheFly | Adaptimmune initiated with a Buy at H.C. Wainwright |
| May 30, 2024 7:11 am | George Farmer | Scotiabank | $3.15 | $1.01 | TheFly | Scotiabank starts Adaptimmune at Outperform ahead of 'imminent' launches |
| May 17, 2024 6:42 am | Graig Suvannavejh | Mizuho Securities | $3.00 | $1.20 | TheFly | Adaptimmune price target lowered to $3 from $9 at Mizuho |
| May 16, 2024 2:45 pm | Peter Lawson | Barclays | $1.00 | $1.20 | StreetInsider | Barclays Reiterates Underweight Rating on Adaptimmune Therapeutics plc (ADAP) |
| November 14, 2022 7:36 am | — | Wells Fargo | $3.00 | $2.51 | Benzinga | Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Raises Price Target to $3 |
No recent news available for ADAPY.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ADAPY.
U.S. House Trading
No House trades found for ADAPY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.